Abstract:ID 92395 Poster Board 511 Opioid Use Disorder (OUD) is a chronic, relapsing disease that, despite our best research efforts, has become a worsening public health crisis. Currently, the medications to treat OUD belong to the opioid class of drugs and, therefore, continue to interact directly with opioid receptors. While these medications are safe and effective for the cessation of opioids with higher abuse potentials, there is still a need for effective non-opioid receptor-targeting therapeutics. Exploring novel non-opioid targets is necessary to overcome this barrier. One such non-opioid target we are currently investigating is the calcitonin gene-related peptide (CGRP) system, particularly CGRP-expressing neurons in the parabrachial nucleus (CGRP PBN ). These neurons have been well studied in itch and pain and are known to project to brain regions implicated in opioid reward and withdrawal. Previous studies in our lab have found that CGRP PBN activity decreases during opioid taking and increases during opioid withdrawal. To further characterize the behavioral role of CGRP PBN neurons in opioid withdrawal, Calca-Cre transgenic mice received viral injections into the PBN containing an inhibitory DREADD (hm4Di), and two weeks later, mice were implanted with 2x25 mg morphine pellets. After five days, morphine withdrawal was induced by removing the pellets. Mice were administered either clozapine-N-oxide (CNO) (3 mg/kg, I.P.) or vehicle (saline, I.P.) 5.5 hours post pellet removal, and behavior was recorded at 6 and 24 hours post pellet removal. Two experimenters scored videos for jumping and wet dog shakes. Those mice injected with CNO showed fewer wet-dog shakes at the 6-hour time than vehicle-injected controls. We next sought to characterize the behavioral role of CGRP PBN neurons in opioid taking. In this experiment, morphine intravenous self-administration (IVSA) was used. Calca-Cre transgenic mice received viral injections into the PBN containing either an inhibitory DREADD (hm4Di) or a control mCherry vector and, two weeks later, were implanted with jugular catheters. Subsequently, operant responding for intravenous morphine was established. After 12 daily sessions, mice were administered CNO (3 mg/kg, I.P.) or vehicle (saline, I.P.) and allowed to respond for morphine. CGRP PBN inhibition reduced morphine intake in hm4Di-injected animals, while those with a control virus maintained their previous levels of morphine intake. Decreases in morphine intake were maintained 24 hours after CNO administration but returned to previous baseline levels at 48 hours. These results suggest that CGRP PBN neurons play a role in the behavioral consequences of both opioid reinforcement and withdrawal. CGRP receptor inhibitors are FDA-approved for the treatment of migraine and exist in both short and long-lasting formulations. By leveraging these available medications for the off-label purpose of treating OUD, we may be able to determine the translational potential of these preclinical findings and, therefore, expand our therapeutic arsenal for long-term maintenance of opioid abstinence and relapse.

Comparison of electroencephalographic changes in response to acute electrical and thermal stimuli with the tail flick and hot plate test in rats administered with opiorphin

Effects of Intrathecal Morphine on Excitatory Amino Acid Contents of Spinal Cord in a Rat Model of Incision Pain

Influence Of Clonidine And Ketamine On M-Rna Expression In A Model Of Opioid-Induced Hyperalgesia In Mice

The Role of Opioid in the Mechanism of the Hypotensive Effect by Simulating Acupuncture on Rat Hindlimb

Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats

Effectiveness Comparisons of G-protein Biased and Unbiased Mu Opioid Receptor Ligands in Warm Water Tail-Withdrawal and Drug Discrimination in Male and Female Rats

Antiallodynic Effects of Systemic and Intrathecal Morphine in the Spared Nerve Injury Model of Neuropathic Pain in Rats

Comparison of Morphine and Endomorphin Analog ZH853 for Tolerance and Immunomodulation in a Rat Model of Neuropathic Pain

Mechanical Antiallodynic Effect of Intrathecal Nefopam in a Rat Neuropathic Pain Model

Effects of Intrathecal κ-Opioid Receptor Agonist on Morphine-induced Itch and Antinociception in Mice

The Opiorphin Analog STR-324 Decreases Sensory Hypersensitivity in a Rat Model of Neuropathic Pain

A comparison between spontaneous electroencephalographic activities induced by morphine and morphine-related environment in rats.

Comparative Pharmacological Profiles of Morphine and Oxycodone under a Neuropathic Pain-Like State in Mice: Evidence for Less Sensitivity to Morphine

Effect of Nocistatin in Pain Modulation

Antinociceptive and morphine modulatory actions of spinal orphanin FQ

Inhibition of Parabrachial CGRP Neurons Reduces Morphine Reinforcement and Withdrawal

A dose-ratio comparison of mu and kappa agonists in formalin and thermal pain

Analgesia Induced By Intrathecal Injection Of Dynorphin-B In The Rat

Nociceptin/orphanin FQ into the rat periaqueductal gray decreases the withdrawal latency to heat and loading, an effect reversed by (Nphe1)nociceptin(1–13)NH2

The Utility of Peripherally Restricted Kappa-Opioid Receptor Agonists for Inhibiting Below-Level Pain after Spinal Cord Injury in Mice

B Rain Opioid-Receptors Are Involved in Mediating Peripheral Electric Stimulation-Induced Inhibition of Morphine Conditioned Place Preference in Rats *